Appropriateness of Using Patient-Derived Xenograft Models for Pharmacologic Evaluation of Novel Therapies for Esophageal/Gastro-Esophageal Junction Cancers

Lorin Dodbiba, Jennifer Teichman, Andrew Fleet, Henry Thai, Maud H. W. Starmans, Roya Navab, Zhuo Chen, Hala Girgis, Lawson Eng, Osvaldo Espin-Garcia, Xiaowei Shen, Bizhan Bandarchi, Joerg Schwock, Ming-Sound Tsao, Hala El-Zimaity, Sandy D. Der, Wei Xu, Robert G. Bristow, Gail E. Darling, Paul C. BoutrosLaurie E. Ailles, Geoffrey Liu

Research output: Contribution to journalArticleAcademicpeer-review

5 Citations (Scopus)
Original languageEnglish
Article numbere0121872
JournalPLOS ONE
Volume10
Issue number3
DOIs
Publication statusPublished - 31 Mar 2015

Cite this

Dodbiba, L., Teichman, J., Fleet, A., Thai, H., Starmans, M. H. W., Navab, R., Chen, Z., Girgis, H., Eng, L., Espin-Garcia, O., Shen, X., Bandarchi, B., Schwock, J., Tsao, M-S., El-Zimaity, H., Der, S. D., Xu, W., Bristow, R. G., Darling, G. E., ... Liu, G. (2015). Appropriateness of Using Patient-Derived Xenograft Models for Pharmacologic Evaluation of Novel Therapies for Esophageal/Gastro-Esophageal Junction Cancers. PLOS ONE, 10(3), [e0121872]. https://doi.org/10.1371/journal.pone.0121872